Twin Stars Shining: The Development Code Behind Ligatech's Two Awards at the 2025 Qingpu Industrial Park

On the afternoon of February 4, the Qingpu Industrial Park 2026 Spring Festival Group Greeting Party was successfully held. District Deputy Secretary Liu Qi, District Standing Committee Member and Deputy District Chief Li Feng and other district leaders attended the event, jointly welcoming the opening year of the "15th Five-Year Plan" with park enterprise representatives. With its breakthrough innovative achievements in the sports medicine field, Shanghai Ligatech Bioscience Co., Ltd. won at oncethe "2025 Innovation Achievement Award"andthe "2025 Courage and Progress Award", two great honors.

Founded in 2014 and focusing on the sports medicine field, Ligatech is committed to building overall solutions from preoperative diagnosis and surgical treatment to postoperative rehabilitation. In 2023, Ligatech successfully launchedthe first domestic artificial ligament, breaking the 20-year market monopoly of imported artificial ligament systems. This product, optimally designed for the body characteristics of Asian people, not only meets or exceeds imported counterparts in key technical indicators such as average breaking tensile force, wear resistance and fatigue resistance, but also greatly shortens patient recovery time from 10 months after traditional surgery to just 3 months.

With multiple patents and a number of core technology products with independent intellectual property rights such as artificial ligaments, Ligatech has been successively recognized as a "High-Tech Enterprise", "Specialized, Refined, Differentiated and Innovative Little Giant Enterprise", "Shanghai Science and Technology Little Giant Cultivation Enterprise", "Shanghai Patent Demonstration Unit" and "Shanghai Municipal Enterprise Technology Center".

Behind Ligatech's "Courage and Progress Award" is a persistence of ten years of sharpening one sword. Since its establishment in 2014, Ligatech has invested huge R&D funds every year. In the centralized procurement that began in 2024, Ligatech's implant products within the scope of centralized procurement obtained a large purchase volume. In particular, Ligatech's artificial ligaments, riding on the momentum of centralized procurement, quickly entered many hospitals and generated effective sales data. Ligatech has also grown from a startup into a group company with rapidly rising annual sales.

Ligatech has also, through investing in innovative enterprises such as TaoImage Medical, built more than 30 product pipelines covering consumables, equipment and imaging + AI, spanning the full process of diagnostic planning, surgical treatment and postoperative evaluation, forming strong technical barriers and industrial synergy effects.

Winning the two awards is a high recognition by Qingpu Industrial Park of Ligatech's growth story over the past 10 years. Ligatech will also leverage its own advantages to better serve patients.